Pharmacotherapy with oral Xa inhibitors for venous thromboembolism

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 5, 2015, Pages 645-658

  Vanassche, Thomas ^a   Vandenbriele, Christophe ^a   Peerlinck, Kathelijne ^a   Verhamme, Peter ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Apixaban; Deep vein thrombosis; Edoxaban; Factor X; Oral anticoagulants; Pulmonary embolism; Rivaroxaban; Venous thromboembolism

Indexed keywords

ANTITHROMBOCYTIC AGENT; APIXABAN; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; EDOXABAN; FONDAPARINUX; HEPARIN; IDRAPARINUX; NONSTEROID ANTIINFLAMMATORY AGENT; RIVAROXABAN; XIMELAGATRAN; BLOOD CLOTTING FACTOR 10A; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; THIAZOLE DERIVATIVE; THIOPHENE DERIVATIVE;

ANTICOAGULANT THERAPY; BODY WEIGHT; CANCER PATIENT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; GERIATRIC PATIENT; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; LACTATION; META ANALYSIS; MODERATE RENAL IMPAIRMENT; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOPHILIA; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; METABOLISM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; CLINICAL TRIALS, PHASE III AS TOPIC; FACTOR XA; FACTOR XA INHIBITORS; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDINES; PYRIDONES; THIAZOLES; THIOPHENES; VENOUS THROMBOEMBOLISM;

EID: 84924409209     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.999043     Document Type: Review

References (35)

1. Kearon C. Natural history of venous thromboembolism. Circulation 2003;107(23 Suppl 1):I22-30
2. Martinelli I, Franchini M, Mannucci PM. How I treat rare venous thromboses. Blood 2008;112(13):4818-23
3. White RH. The epidemiology of venous thromboembolism. Circulation 2003;107(23 Suppl 1):I4-8
4. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):381S-453S
5. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007;98(4):756-64
6. Murray GD, Best CH. The use of heparin in thrombosis. Ann Surg 1938;108(2):163-77
7. Schulman S. Treatment of venous thromboembolism with dabigatran. Curr Opin Pulm Med 2012;18(5):410-15
8. EINSTEIN Investigators. Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363(26):2499-510
9. EINSTEIN-PE Investigators. Buller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366(14):1287-97
10. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369(9):799-808
11. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013;368(8):699-708
12. Hokusai VTEI, Buller HR, Decousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013;369(15):1406-15
13. Buller HR, Halperin JL, Bounameaux H, Prins M. Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants. J Thromb Haemost 2008;6(2):227-9
14. Casteels M, Flamion B. Open-label trials and drug registration: a European regulator's view. J Thromb Haemost 2008;6(2):232-4
15. Brandjes DP, Heijboer H, Buller HR, et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992;327(21):1485-9
16. van Gogh I, Buller HR, Cohen AT, et al. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007;357(11):1094-104
17. Schulman S, Wahlander K, Lundstrom T, et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003;349(18):1713-21
18. van Es N, Coppens M, Schulman S, et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014;124(12):1968-75
19. Greenberg PD, Cello JP, Rockey DC. Relationship of low-dose aspirin to GI injury and occult bleeding: a pilot study. Gastrointest Endosc 1999;50(5):618-22
20. Geldhof V, Vandenbriele C, Verhamme P, Vanassche T. Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants. Thromb J 2014;12:21
21. Bristol-Myers Squibb, Pfizer EEIG. Eliquis®(apixaban) Summary of Product Characteristics. 2011. Available from: http://www.medicines.org.uk/EMC/medicine/24988
22. Bayer Pharma AG. Xarelto® (rivaroxaban) Summary of Product Characteristics. 2012. Available from: http://www.xarelto.com/html/downloads/Xareltoprescribing-information-nov-2012.pdf
23. Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e691S-736S
24. Lyman GH. Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer 2011;117(7):1334-49
25. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(2 Suppl):e419S-94S
26. Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(2 Suppl):e227S-77S
27. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e195S-226S
28. Vedovati MC, Germini F, Agnelli G, Becattini C. Direct oral anticoagulants in patients with venous thromboembolism and cancer: a systematic review and meta-analysis. Chest 2014. [Epub ahead of print]
29. van der Hulle T, Huisman MV, Klok FA. Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism: reply. J Thromb Haemost 2014. [Epub ahead of print]
30. Carrier M, Cameron C, Delluc A, et al. Efficacy and safety of anticoagulant therapy for the treatment of acute cancerassociated thrombosis: a systematic review and meta-analysis. Thromb Res 2014;134(6):1214-19
31. Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009;374(9683):29-38
32. Authors/Task Force Members. Konstantinides SV, Torbicki A, et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Endorsed by the European Respiratory Society (ERS). Eur Heart J 2014;35(43):3033-73
33. Kearon C. Influence of hereditary or acquired thrombophilias on the treatment of venous thromboembolism. Curr Opin Hematol 2012;19(5):363-70
34. Linkins LA, Warkentin TE, Pai M, et al. Design of the rivaroxaban for heparininduced thrombocytopenia study. J Thromb Thrombolysis 2014;38(4):485-92
35. Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15(5):625-51